se of Laghu Talisadi Churna and Salbutamol in management of Bronchial Asthma.
Phase 2
- Conditions
- Health Condition 1: J459- Other and unspecified asthma
- Registration Number
- CTRI/2024/03/063781
- Lead Sponsor
- Dr Avadhut Vitthal Khabale
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of any gender
Age 18 to 70 years
Recently diagnosed case of Bronchial Asthma
FEV1 35 to 79%
Exclusion Criteria
K/C/O -Chronic obstructive pulmonary disease.
K/C/O - Infective pulmonary pathology.
Any systemic disorder i.e. K/C/O renal & Cardiac disorders.
K/C/O- immuno-compromised disease
K/C/O- Malignancy disease
K/C/O-Chornic Interstitial Lung Disease
Pregnant and lactating women
k/C/O-Diabetes mellitus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •To assess the symptomatic relief . <br/ ><br>•To find out the effect of Laghu Talisadi Churna on FEV1 <br/ ><br>Timepoint: Assessment on 0th 7th 14th 21th 28th days.
- Secondary Outcome Measures
Name Time Method •To observe any association between Tamak Shwas and raised IgE levels? <br/ ><br> And If there is association, it is a study showing that the study drug <br/ ><br> lowers IgE levels. <br/ ><br>Timepoint: Assessment on 0th 7th 14th 21th 28th days.